C. Rivera-Guevara et al. / Bioorg. Med. Chem. 18 (2010) 5593–5601
3. Swain, S. M. J. Clin. Oncol. 2001, 19, 93.
5601
HPV copy number, different amounts of ERs and tamoxifen
concentration (probably tamoxifen has different targets at higher
concentrations avoiding its antiproliferative effects). Thus, it would
be very important to test the effects of PCTDs on cell proliferation of
different cervical cancer cells, both in cancer cell lines and primary
cultures from different patients. Whether or not such variable re-
sponse would be eliminated by PCTDs remains to be elucidated. It
will be also very important to discover additional targets of PCTDs.
Actually, the effect of PCTDs on cell proliferation might be also ex-
plained by the inhibition of some ion channels for example the ether
à-go-go related gene potassium channel (Kv11.x), which is known to
be inhibited by tamoxifen and to be an advantage for proliferation of
several cancer cells.39,18
4. Berry, J.; Green, B. J.; Matheson, D. S. Eur. J. Cancer Clin. Oncol. 1987, 23, 517.
5. Gundimeda, U.; Chen, Z.; Gopalakrishna, R. J. Biol. Chem. 1996, 271, 13504.
6. Pollak, M.; Costantino, J.; Polychronakos, C.; Blauer, S. A.; Guyda, H.; Redmund,
C.; Fisher, B.; Margolese, R. J. Natl. Cancer Inst. 1990, 82, 1693.
7. Gagliardi, A.; Collins, D. C. Cancer Res. 1993, 53, 533.
8. Sahebgharani, M.; Hardy, S. P.; Lloyd, A. W.; Hunter, A. C.; Allen, M. C. Cell.
Physiol. Biochem. 2001, 11, 99.
9. Allen, M. C.; Newland, C.; Valverde, M. A.; Hardy, S. P. Eur. J. Pharmacol. 1998,
354, 261.
10. Sartor, P.; Vancher, P.; Mollard, P.; Dufy, B. Endocrinology 1998, 123, 534.
11. Valverde, M. A.; Mintenig, G. M.; Sepúlveda, F. V. Pflüg Arch. 1993, 425,
552.
12. Zhang, J. J.; Jacob, T. J.; Valverde, M. A.; Hardy, S. P.; Mintenig, G. M.; Sepulveda,
F. V.; Gill, D. R.; Hyde, S. C.; Trezise, A. E. O.; Higgins, C. F. J. Clin. Invest. 1994, 94,
1690.
13. Hardy, S. P.; de Felipe, C.; Valverde, M. A. FEBS Lett. 1998, 434, 236.
14. Allen, M. C.; Gale, P. A.; Hunter, A. C.; Lloyd, A.; Hardy, S. P. Biochem. Biophys.
Acta Biomembr. 2000, 1509, 229.
15. Sha, Y.; Tashima, T.; Mochizuki, Y.; Toriumi, Y.; Adachi-Akahane, S.; Nonomura,
T.; Cheng, M. S.; Ohwada, T. Chem. Pharm. Bull. 2005, 53, 1372.
16. Bolanz, K. A.; Hediger, M. A.; Landowski, C. P. Mol. Cancer Ther. 2008, 7, 271.
17. Perez, G. J. J. Biol. Chem. 2005, 280, 21739.
Despite a quantitative study of the intracellular concentration
of PCTDs is necessary and the precise mechanism by which PCTDs
enter the cells remains elusive, here we show that PCTDs display
genomic action by affecting transcriptional activity of ER
a and
influence cancer cell proliferation. The values obtained (retention
time value, m/z ratio and fragmentation pattern) for the standard
solutions using the compounds in the micromolar range, and the
agonistic effects of two PCTDs alone on the transcriptional activity
show that the compounds are not contaminated with possible
unmodified tamoxifen. To our knowledge, three of these PCTDs,
namely, tamoxifen isopropyl bromide, tamoxifen methyl bromide
and tamoxifen propyl bromide, are new compounds not previously
reported.
18. Thomas, D.; Gut, B.; Karsai, S.; Wimmer, A. B.; Wu, K.; Wnedt-Nordhal, G.;
Zhang, W.; Kathöfer, S.; Schoels, W.; Katus, H. A.; Kiehn, J.; Karle, C. A. Naunyn-
Schmiedeberg’s Arch. Pharmacol. 2003, 368, 41.
19. Marrero-Alonso, J.; García Marrero, B.; Gómez, T.; Díaz, M. Eur. J. Pharmacol.
2006, 532, 115.
20. Dietze, E. C.; Troch, M. M.; Bean, G. R.; Heffner, J. B.; Bowie, M. L.; Rosenberg, P.;
Ratliff, B. Oncogene 2004, 23, 3851.
21. Dick, G. M.; Hunter, A. C.; Sanders, K. M. Mol. Pharmacol. 2002, 61, 1105.
22. Biegon, A.; Brewster, M. E.; Hadassa, D.; Emil, P.; Dalia, S.; Alvin, M. K. Cancer
Res. 1996, 56, 4328.
23. Somjen, D.; Waisman, A.; Kaye, A. M. J. Steroid. Biochem. Mol. Biol. 1996, 59, 389.
24. Brewster, M. E.; Yael, P.; Edna, R.; Biegon, A.; Emil, P.; Hadassa, D. Int. J. Pharm.
1997, 153, 147.
5. Conclusions
25. Biegon, A.; Brewster, M. E. PCT Int. Appl. 1998, 44.
26. Jarman, J.; Leung, O. T.; Leclercq, G.; Devleeschouwer, N.; Stoessel, S.; Coombes,
R. C.; Skilton, R. A. Anti-Cancer Drug Disc. 1996, I, 259.
27. Reel, J. R.; Humphrey, R. R.; Shih, H.; Windsor, B. L.; Sakowski, R.; Creger, P. L.;
Edgren, R. A. Fertil. Steril. 1979, 31, 552.
Due to the relevance of tamoxifen in oncology, the necessity to
have new anticancer drugs, and in order to gain insights into the
mechanisms of action of permanently charged tamoxifen deriva-
tives, we synthesized, characterized, and studied the genomic ac-
tions of these compounds including three new derivatives. Our
results strongly suggest genomic effects as a mechanism of action
of permanently charged tamoxifen derivatives. Detection of com-
pounds in cell lysates and gene reporter studies provide more
accurate information on their potential effects and mechanisms
of action. This approach could lead to a better design of new ther-
apeutic molecules and help to elucidate molecular mechanisms of
new anticancer drugs.
28. Cheng, Y.; Prusoff, W. H. Biochem. Pharmacol. 1973, 22, 3099.
29. Farias, L. M. B.; Ocaña, D. B.; Díaz, L.; Larrea, F.; Avila-Chávez, E.; Cadena, A.;
Hinojosa, L. M.; Lara, G.; Villanueva, L. A.; Vargas, C.; Hernández-Gallegos, E.;
Camacho-Arroyo, I.; Dueñas-González, A.; Pérez-Cárdenas, E.; Pardo, L. A.;
Morales, A.; Taja-Chayeb, L.; Escamilla, J.; Sánchez-Peña, C.; Camacho, J. Cancer
Res. 2004, 64, 6996.
30. Tetko, I. V.; Gasteiger, J.; Todeschini, R.; Mauri, A.; Livingstone, D.; Ertl, P.;
Palyulin, V. A.; Radchenko, E. V.; Zefirov, N. S.; Makarenko, A. S.; Tanchuk, V. Y.;
Prokopenko, V. V. J. Comput. Aided Mol. Des. 2005, 19, 453.
31. Díaz, L.; Ceja-Ochoa, I.; Restrepo-Angulo, I.; Larrea, F.; Avila-Chávez, E.; García-
Becerra, R.; Borja-Cacho, E.; Barrera, D.; Ahumada, E.; Gariglio, P.; Alvarez-Rios,
E.; Ocadiz-Delgado, R.; Garcia-Villa, E.; Hernandez-Gallegos, E.; Camacho-
Arroyo, I.; Morales, A.; Ordaz-Rosado, D.; Garcia-Latorre, E.; Escamilla, J.;
Sánchez-Peña, L. C.; Saqui, M.; Gamboa-Dominguez, A.; Vera, E.; Uribe-
Ramirez, M.; Murbartian, J.; Ortiz, C. S.; Rivera-Guevara, C.; De Vizcaya, A.;
Camacho, J. Cancer Res. 2009, 69, 3300.
Acknowledgments
32. Fisher, H.; Kansy, M.; Avdeef, A.; Senner, F. Eur. J. Pharmacol. Sci. 2007, 31, 32.
33. Jordan, V. C. J. Natl. Cancer Inst. 2007, 99, 350.
34. Jordan, V. C. Pharmacol. Rev. 1984, 36, 245.
We thank Verónica Cadena for her secretarial work, and Guada-
lupe Montiel and Rosa Elena Flores for their technical assistance.
This work was partially supported by Consejo Nacional de Ciencia
y Tecnología (Grant 45753 to J.C.).
35. Michalides, R.; Griekspoor, A.; Balkenende, A.; Verwoerd, D.; Janssen, L.; Jalink,
´
K.; Floore, A.; Velds, A.; vant Veer, L.; Neefjes, J. Cancer Cell 2004, 5, 597.
36. Grenman, S.; Shapira, A.; Carey, T. E. Gynecol. Oncol. 1988, 30, 228.
37. Hwang, J. Y.; Lin, B. Y.; Tang, F. M.; Yu, W. C. Y. Cancer Res. 1992, 52, 6848.
38. Roig, L. M. V.; Lotfi, H.; Olcese, J. E.; Castro, G. L.; Ciocca, D. R. Anticancer Res.
1993, 13, 2457.
References and notes
39. Bianchi, L.; Wible, B.; Arcangeli, A.; Taglialatela, M.; Morra, F.; Castaldo, P.;
Crociani, O.; Rosati, B.; Faravelli, L.; Olivotto, M.; Wanke, E. Cancer Res. 1998, 58,
815.
1. Jordan, V. C. Nat. Rev. Drug Disc. 2003, 2, 205.
2. Singh, M. N.; Strigfellow, H. F.; Paraskevaidis, E.; Martin-Hirsch, P. L.; Martin, F.
L. Cancer Treat. Rev. 2007, 33, 91.